July 3, 2012, Jiangsu Aosaikang Pharmaceutical Co.,Ltd. (“Aosaikang Pharmaceutical”) obtained approval for A share issuance from China Security Regulatory Commission (“CSRC”). It planned to launch its initial public offering of 700 million shares on ChiNext.

Aosaikang Pharmaceutical is primarily engaged in R&D, manufacture and sales of digestive and oncology drugs. One of its main products omeprazole sodium enjoys independent pricing power entitled by National Development and Reform Commission. Its consolidated gross margin ranks the first among the listed companies principally undertaking chemical business.

Jingtian & Gongcheng advised the lead underwriter China International Capital Corporation Limited.